SCHEMBL4128315

SCHEMBL4128315

COc1cc(-c2ccc(/C=C3/SC(Nc4ccc(C(CCCC(C)C)C(=O)O)cc4)=NC3=O)cc2)cc(CO)c1O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 8/20 0.37
MEN1 O00255 7/20 0.37
MAPT P10636 6/20 0.37
ALDH1A1 P00352 5/20 0.37
HPGD P15428 4/20 0.37
LMNA P02545 3/20 0.37
KDM4E B2RXH2 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
PSMD14 O00487 2/20 0.37
MMP2 P08253 1/20 0.37
G6PD P11413 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ALOX5 P09917 11/20 0.36
GAA P10253 2/20 0.35
PTPN1 P18031 2/20 0.34
HKDC1 Q2TB90 1/20 0.34
POLB P06746 2/20 0.33
RECQL P46063 1/20 0.33
HTT P42858 2/20 0.32
TNNI3 P19429 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4128320 1.00 KMT2A (0.37) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL4140448 0.82 ALOX5 (0.36) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL4140451 0.82 ALOX5 (0.36) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL4126192 0.77 ALOX5 (0.39) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL4126194 0.77 ALOX5 (0.39) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL4128676 0.72 PRMT5 (0.47) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL4128679 0.72 PRMT5 (0.47) KMT2AMEN1MAPTALDH1A1HPGD
SCHEMBL4133702 0.72 MEN1 (0.37) KMT2AMEN1ALDH1A1L3MBTL1ALOX5
SCHEMBL4133696 0.72 MEN1 (0.37) KMT2AMEN1ALDH1A1L3MBTL1ALOX5
SCHEMBL4634853 0.71 ACKR3 (0.35) KMT2AMEN1ALOX5PTPN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ KMT2A 2895/4885MEN1 4075/4885MAPT 3532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.